Viking Therapeutics is advancing its GLP-1/GIP drug, VK2735, which has demonstrated the ability to help individuals maintain weight loss in clinical trials. This development positions VK2735 as a potential competitor to Eli Lilly’s Zepbound.
The positive results have led to a significant increase in Viking Therapeutics' stock value, reflecting investor confidence in the drug's market potential and its implications for obesity treatment.
As VK2735 progresses, watch for updates on its regulatory pathway and potential partnerships. The drug's success could reshape obesity treatment strategies and influence market dynamics, particularly against established players like Zepbound.